Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 7/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 9/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanisoquin SCHEMBL29801607 | 0.93 | LMNA (0.68) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Guanisoquin SCHEMBL121149 | 0.93 | LMNA (0.68) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Guanisoquin SCHEMBL17894488 | 0.88 | ABHD6 (0.57) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL29627959 | 0.86 | DPP8 (0.48) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL1648407 | 0.81 | TMPRSS2 (0.63) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL8544496 | 0.81 | TMPRSS2 (0.63) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL1648408 | 0.81 | TMPRSS2 (0.63) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL31598007 | 0.79 | ABHD6 (0.59) | ABHD6CARM1 | |
| SCHEMBL3808915 | 0.79 | ABHD6 (0.59) | ABHD6CARM1 | |
| Debrisoquin SCHEMBL29390380 | 0.78 | TMPRSS2 (1.00) | TMPRSS2HTR1AADRA2ACYP2D6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6559186-B1 | Pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2- adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic | ARC 1, INC. | 2003-05-06 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-4656291-A | OXIDIZING THIOUREA DERIVATIVE WITH HYDROGEN PEROXIDE IN PRESENCE OF MOLYBDENUM CATALYST | MCNEILAB, INC. (US) | 1987-04-07 | — | — | US | disclosed |
| US-4283407-A | ANTIHYPERTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1981-08-11 | — | — | US | disclosed |
| US-4075208-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-3956335-A | HYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | TMPRSS2 1287/4885HTR1A 16/4885ADRA2A 215/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | TMPRSS2 1287/4885HTR1A 16/4885ADRA2A 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.